Raymond James Financial Inc. Acquires 460,021 Shares of Cellebrite DI Ltd. $CLBT

Key Points

• Raymond James Financial Inc. significantly increased its stake in Cellebrite DI Ltd. by 101.4%, holding approximately $17.75 million worth of shares.
• Cellebrite DI's shares rose 4.2%, with a market capitalization of approximately $3.94 billion and a current share price of $16.47.
• Recent earnings reports indicated that Cellebrite DI beat earnings expectations with $0.12 EPS for the quarter, and revenue grew by 18.4% year-over-year.

Raymond James Financial Inc. lifted its stake in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 101.4% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 913,721 shares of the company's stock after purchasing an additional 460,021 shares during the quarter. Raymond James Financial Inc. owned 0.38% of Cellebrite DI worth $17,754,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also made changes to their positions in CLBT. NewEdge Advisors LLC lifted its position in shares of Cellebrite DI by 600.7% in the fourth quarter. NewEdge Advisors LLC now owns 3,910 shares of the company's stock worth $86,000 after purchasing an additional 3,352 shares in the last quarter. Aquatic Capital Management LLC purchased a new stake in shares of Cellebrite DI in the fourth quarter worth approximately $1,015,000. Public Employees Retirement Association of Colorado purchased a new stake in shares of Cellebrite DI in the fourth quarter worth approximately $465,000. Northern Trust Corp lifted its position in shares of Cellebrite DI by 113.6% in the fourth quarter. Northern Trust Corp now owns 211,994 shares of the company's stock worth $4,670,000 after purchasing an additional 112,731 shares in the last quarter. Finally, AQR Capital Management LLC purchased a new stake in shares of Cellebrite DI in the fourth quarter worth approximately $16,205,000. 45.88% of the stock is owned by hedge funds and other institutional investors.

Cellebrite DI Stock Down 0.2%

CLBT stock traded down $0.04 during midday trading on Tuesday, hitting $16.36. 1,600,435 shares of the company traded hands, compared to its average volume of 2,341,530. Cellebrite DI Ltd. has a twelve month low of $13.10 and a twelve month high of $26.30. The business has a 50 day simple moving average of $15.01 and a 200-day simple moving average of $17.10. The stock has a market capitalization of $3.92 billion, a price-to-earnings ratio of -21.53, a price-to-earnings-growth ratio of 2.98 and a beta of 1.28.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its quarterly earnings results on Thursday, August 14th. The company reported $0.12 EPS for the quarter, beating the consensus estimate of $0.11 by $0.01. Cellebrite DI had a positive return on equity of 23.92% and a negative net margin of 34.56%.The company had revenue of $113.28 million for the quarter, compared to the consensus estimate of $112.33 million. During the same quarter last year, the company posted $0.10 earnings per share. The company's revenue for the quarter was up 18.4% compared to the same quarter last year. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities research analysts forecast that Cellebrite DI Ltd. will post 0.3 EPS for the current year.

Analysts Set New Price Targets

CLBT has been the subject of a number of research analyst reports. Wall Street Zen raised shares of Cellebrite DI from a "hold" rating to a "buy" rating in a research report on Saturday, August 16th. Lake Street Capital dropped their price objective on Cellebrite DI from $24.00 to $22.00 and set a "buy" rating on the stock in a report on Friday, August 15th. Needham & Company LLC dropped their price objective on Cellebrite DI from $24.00 to $18.00 and set a "buy" rating on the stock in a report on Thursday, August 14th. Finally, JPMorgan Chase & Co. dropped their price objective on Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating on the stock in a report on Monday, May 12th. Five equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $22.40.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.